Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination With the Most Commonly Used Statins - Evacetrapib Dose Ranging Study


The goal of the trial was to evaluate treatment with evacetrapib as monotherapy or in addition to a statin compared with placebo among patients with dyslipidemia (high low-density lipoprotein cholesterol [LDL-C] or low high-density lipoprotein cholesterol [HDL-C]).

Evacetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor.